186 results on '"Krause, S W"'
Search Results
2. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
3. P545: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19
4. Immature platelets do not reliably predict platelet recovery in patients with intensive chemotherapy or stem cell transplantation
5. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
6. Cellular Immunotherapy of Cancer: Adoptive Transfer of Monocyte-Derived Tumorcytotoxic Macrophages
7. Monocyte-Derived Cells in Adoptive Immunotherapy of Cancer: Facts and Perspectives
8. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
9. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
10. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
11. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
12. Akuttherapie onkologischer Notfälle
13. Inzidenz, Ursachen und Prognose von Organversagen bei Patienten mit malignen Erkrankungen
14. G-DRG-System in der Onkologie: Probleme und Chancen
15. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
16. Blood leukocyte subsets and cytokine profile after autologous peripheral blood stem cell transplantation
17. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
18. Limited resources in oncology: A survey among the members of the German Society of Hematology and Oncology (DGHO): V789
19. Hodgkin lymphoma - treatment of older patients: V740
20. 12 month molecular response < 1% BCR-ABL (IS) is associated with improved overall and progression-free survival in CML patients: V635
21. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: The randomized German CML-Study IV: V633
22. Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV: V632
23. The prognostic significance of molecular and cytogenetic response landmarks after 3 months of imatinib in the upfront treatment of chronic myeloid leukemia: V637
24. Autologous T cells from AML patients can be effectively recruited for in-vitro lysis of blasts by a novel CD33/CD3-bispecific BiTE antibody: V398
25. Optimization of Imatinib Therapy By Combination. 5 Year Survival and Response; Results of the Pilot Phase of the Randomized German CML Study IV: FV326
26. OPTIMIZATION OF IMATINIB THERAPY BY COMBINATION, DOSE ESCALATION AND TRANSPLANTATION. DESIGNED FIRST INTERIM ANALYSIS OF THE RANDOMIZED GERMAN CML STUDY IV: V54
27. Early Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term PFS and EFS in CP-CML - an Interim Analysis of the Randomized German CML Study IV.: V55
28. Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study
29. DRG in der Hämatologie und Internistischen Onkologie: Ergebnisse aus zwei deutschlandweiten Evaluationsprojekten
30. Developmental regulation of granulocyte-macrophage colony-stimulating factor production during human monocyte-to-macrophage maturation
31. Pioglitazone and Rofecoxib Combined with Angiostatic Scheduling of Capecitabine in Advanced Cholangiocarcinoma: O236
32. Treatment of Peripheral (Mature) T-Cell Lymphomas with Alemtuzumab, Fludarabine, Cyclophosphamide and Doxorubicin (Campath-FCD) - Preliminary Results of a Phase II Study: O116
33. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in advanced renal cell carcinoma: P973
34. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in advanced biliary tract cancer and hepatocellular carcinoma: P777
35. The number of IFN-gamma secreting anti host reactive T cells correlates with GvH disease after allogeneic transplantation: P477
36. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in secondline therapy of advanced melanomas and pre-treated soft tissue sarcomas: V382
37. Characterization of TLR2 promoter polymorphisms in sepsis patients: 706
38. Characterization of regulatory elements controlling the maturation-associated expression of human Carboxypeptidase M (CPM) during monocytic differentiation: 658
39. Active demethylation of the MCP-4 promoter in monocytederived dendritic cells: 635
40. A phase I/II trial of heat shock protein 70-peptide stimulated NK cells in patients with malignant disease: 400
41. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in far advanced malignancies: 87
42. 7 Isolation, Characterization and Cultivation of Human Monocytes and Macrophages
43. Decreased T Cell Stimulatory Capacity of Monocyte-Derived Human Macrophages following Herpes simplex Virus Type 1 Infection
44. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells
45. Granulocyte-macrophage colony-stimulating factor modulates lipopolysaccharide (LPS)-binding and LPS-response of human macrophages: inverse regulation of tumour necrosis factor-α and interleukin-10
46. Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial
47. The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival : Updated results from long-term follow-up of the randomized-controlled SORAML trial
48. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccocus aureus in human monocytes
49. First two operational years of the electron-beam ion trap charge breeder at the National Superconducting Cyclotron Laboratory
50. On-line operation of the EBIT charge breeder of the ReA post-accelerator
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.